Pantodac Dsr Capsule

Pantodac Dsr Capsule is a combination of two medicines such as domperidone and pantoprazole. It is used to treat conditions like gastroesophageal reflux disease (Acid reflux), erosive esophagitis, gastritis, and indigestion.

It works by reducing the amount of acid in the stomach which helps in relief of acid related indigestion & heartburn. It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.

​

• Treatment of Gastroesophageal reflux disease (Acid reflux)
• Treatment of Erosive esophagitis
• Treatment of Gastritis
• Treatment of Indigestion

Most side effects of Pantodac Dsr Capsule do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.

Common side effects include:

• Dryness in mouth

• The dosage and duration of the Pantodac Dsr Capsule are decided by the doctor based on the severity of the condition and other health factors. Take this tablet on an empty stomach for better results.
• Before starting this medicine, please inform your doctor about your medical history. If you experience any signs and symptoms while eating this medication that are not manageable, do not ignore those symptoms because they may lead to a higher risk.​​
  

• Pantodac Dsr Capsule is a combination of two medicines such as domperidone and pantoprazole. In which Domperidone known as prokinetic agent works on the upper digestive system to make the stomach and intestines flow more freely, making it easier for food to pass through the stomach.
• Also, Pantoprazole is a proton pump inhibitor (PPI) which help to treat acid-related indigestion and heartburn by lowering the amount of acid production in the stomach.​
  

• McQuaid, K. R. (2018). Drugs used in the treatment of gastrointestinal diseases. Basic & clinical pharmacology, 12. https://accessmedicine.mhmedical.com/content.aspx?bookid=2988&sectionid=250604938
• Sivakumar, T., Manavalan, R., Muralidharan, C., & Valliappan, K. (2007). Multi-criteria decision making approach and experimental design as chemometric tools to optimize HPLC separation of domperidone and pantoprazole. Journal of Pharmaceutical and Biomedical Analysis, 43(5), 1842-1848. https://pubmed.ncbi.nlm.nih.gov/17208403/
• Taghvaei, T., Kazemi, A., Hosseini, V., Hamidian, M., Fakheri, H. T., Hashemi, S. A., & Maleki, I. (2018). Evaluation of the additive effect of domperidone on patients with refractory gastroesophageal reflux disease; a randomized double blind clinical trial. Middle East Journal of Digestive Diseases, 11(1), 24. https://pubmed.ncbi.nlm.nih.gov/31049179/
• Puranik, R. U., Karandikar, Y. S., Bhat, S. M., & Patil, V. A. (2018). Pharmacoeconomic Evaluation of Pantoprazole and Pantoprazole Plus Domperidone in Treatment of Patients with GERD. Journal of Clinical & Diagnostic Research, 12(11). https://www.jcdr.net/ReadXMLFile.aspx?id=12267
• Zamani, N. F., Sjahid, A. S., Tuan Kamauzaman, T. H., Lee, Y. Y., & Islam, M. A. (2022). Efficacy and safety of domperidone in combination with proton pump inhibitors in gastroesophageal reflux disease: a systematic review and meta-analysis of randomised controlled trials. Journal of Clinical Medicine, 11(18), 5268. https://pubmed.ncbi.nlm.nih.gov/36142915/
• Srivastava, S., Srivastava, S., Rehman, M., Agarwal, V., Chaudhary, R., Kaushik, A. S., ... & Mishra, V. (2024). LONG-TERM ORAL DOSE TOXICITY STUDY OF DOMPERIDONE WITH PANTOPRAZOLE IN MALE WISTAR RATS. Biochemical & Cellular Archives, 24(2).